TaiGen Biopharmaceuticals Holdings Limited (TPEX:4157)
Taiwan · Delayed Price · Currency is TWD 9.03
-0.14 (-1.53%)
Sep 8, 2026, 12:48 PM CST
TPEX:4157 Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 256.46 | 259.47 | 150.65 | 123.13 | 36.23 | 1,295 | |
Revenue Growth | 530.40% | 72.23% | 22.35% | 239.87% | -97.20% | 5426.95% |
Cost of Revenue | 16.18 | 18.17 | 16.13 | 11.45 | 3.74 | 12.72 |
Gross Profit | 240.28 | 241.3 | 134.52 | 111.69 | 32.49 | 1,282 |
Selling, General & Admin | 75.37 | 75.02 | 90.55 | 98.9 | 72.64 | 99.06 |
Research & Development | 82.24 | 96.88 | 166.07 | 187.48 | 237.52 | 283.28 |
Operating Expenses | 157.61 | 171.91 | 256.62 | 286.39 | 310.16 | 382.34 |
Operating Income | 82.67 | 69.4 | -122.1 | -174.7 | -277.67 | 899.46 |
Interest Expense | -0.9 | -1.67 | -1.42 | -1.14 | -0.85 | -0.24 |
Interest & Investment Income | 14.62 | 18.47 | 24.4 | 20.38 | 8.72 | 4.23 |
Earnings From Equity Investments | - | - | - | - | - | -23.24 |
Currency Exchange Gain (Loss) | -33.4 | -33.4 | 54.17 | -15.68 | 51.79 | -4.24 |
Other Non Operating Income (Expenses) | 101.82 | 1.46 | 0.48 | 149.4 | 0.01 | 0.04 |
EBT Excluding Unusual Items | 164.82 | 54.26 | -44.47 | -21.73 | -218 | 876 |
Gain (Loss) on Sale of Investments | 2.47 | 2.47 | 13.55 | 165.22 | 0.3 | 0.08 |
Gain (Loss) on Sale of Assets | 1.45 | 1.45 | - | - | - | -0.08 |
Asset Writedown | -0.74 | -0.74 | -1.96 | - | -12.06 | - |
Pretax Income | 168 | 57.44 | -32.89 | 143.49 | -229.77 | 875.99 |
Income Tax Expense | 12.89 | 12.26 | 5.7 | 6.76 | 7.4 | 100.37 |
Net Income | 155.12 | 45.18 | -38.58 | 136.73 | -237.16 | 775.62 |
Net Income to Common | 155.12 | 45.18 | -38.58 | 136.73 | -237.16 | 775.62 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 708 | 716 | 717 | 717 | 717 | 717 |
Shares Outstanding (Diluted) | 708 | 716 | 717 | 717 | 717 | 717 |
Shares Change | -1.31% | -0.19% | 0.03% | 0.06% | -0.07% | 0.07% |
EPS (Basic) | 0.22 | 0.06 | -0.05 | 0.19 | -0.33 | 1.08 |
EPS (Diluted) | 0.22 | 0.06 | -0.05 | 0.19 | -0.33 | 1.08 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 51.89 | 19.48 | -173.62 | 3.57 | -24.66 | 618.83 |
Free Cash Flow Per Share | 0.07 | 0.03 | -0.24 | 0.01 | -0.03 | 0.86 |
Gross Margin | 93.69% | 93.00% | 89.29% | 90.70% | 89.69% | 99.02% |
Operating Margin | 32.24% | 26.74% | -81.05% | -141.88% | -766.41% | 69.48% |
Profit Margin | 60.48% | 17.41% | -25.61% | 111.04% | -654.61% | 59.91% |
Free Cash Flow Margin | 20.23% | 7.51% | -115.25% | 2.90% | -68.06% | 47.80% |
EBITDA | 80.03 | 73.06 | -113.76 | -164.59 | -267.53 | 909.9 |
EBITDA Margin | 31.21% | 28.16% | -75.51% | -133.67% | - | 70.29% |
D&A For EBITDA | -2.64 | 3.67 | 8.34 | 10.11 | 10.14 | 10.44 |
EBIT | 82.67 | 69.4 | -122.1 | -174.7 | -277.67 | 899.46 |
EBIT Margin | 32.24% | 26.74% | -81.05% | -141.88% | - | 69.48% |
Effective Tax Rate | 7.67% | 21.35% | - | 4.71% | - | 11.46% |